---
schema_version: "secwatch.filing_event.v1"
accession: "0001171520-21-000432"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2021-11-02T23:59:59+00:00"
generated_at: "2026-06-28T14:57:03.130950+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro appoints renowned neurosurgeon Dr. Linda M. Liau to Board

## Summary
- Board expanded from 7 to 8 members; Dr. Liau appointed to newly created directorship effective Nov 2, 2021.
- Dr. Liau is Professor and W. Eugene Stern Chair of Neurosurgery at UCLA, Co-Director of UCLA Brain Tumor Center.
- She receives $40,000 annual retainer and initial equity grant valued at $120,000 vesting over one year.
- Compensation includes annual equity grants of $120,000 on the day after each annual meeting.
- No arrangements with any other person; no related-party transactions disclosed.

## SEC filing metadata
- accession: 0001171520-21-000432
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2021-11-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000117152021000432/0001171520-21-000432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000117152021000432/eps9887.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171520-21-000432
- JSON: https://secwatch.observer/filing/0001171520-21-000432.json
- Plain text: https://secwatch.observer/filing/0001171520-21-000432.txt

## Key facts
- Executive change
  Linda M. Liau was appointed as Director at ClearPoint Neuro, Inc..
  - Action: appointed
  - Role: Director
  source text: On November 2, 2021, the Board of Directors (the “ Board ”) of ClearPoint Neuro, Inc. (the “ Company ”) increased the size of the Board from seven to eight members, and, with the recommendation of the Corporate Governance and Nominating Committee of the Board, appointed Linda M. Liau, MD, PhD, MBA to fill the newly created directorship, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285550/000117152021000432/0001171520-21-000432-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.